Bharat Biotech's COVID-19 nasal vaccine phase III trials completed
India | June 19, 2022 6:54 ISTKrishna was in Paris as a speaker at Viva Technology 2022 where India was declared country of the year.
Krishna was in Paris as a speaker at Viva Technology 2022 where India was declared country of the year.
A press release from the vaccine maker said the study has been accepted and published in Lancet Infectious diseases, peer-reviewed high impact factor journal.
The DCGI in April also granted an emergency use authorisation (EUA) to Covaxin for the age group of 6-12 years.
This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years.
Recently, in a statement on WHO's suspension of Covaxin, Bharat Biotech said, "For the millions who have received Covaxin, the vaccine certificates issued still stand valid as there is no impact on efficacy and safety of the vaccine."
Earlier on Sunday, Bharat Biotech had said it had nothing else to add to an earlier statement where it said it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.
The vaccine manufacturer has further said that the company is slowing down the production of Covaxin for facility optimization.
The company said after the recent WHO post Emergency Use Listing (EUL) inspection, it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.
An intranasal vaccine as a booster dose if becomes a reality would be easier to administer in mass vaccination campaigns and has the potential to prevent transmission.
Earlier, Hyderabad-based Hyderabad-based vaccine manufacturer had claimed that its COVID vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus.
Covaxin ( BBV152) booster, India's indigenous vaccine, has shown that it can neutralize both Omicron and Delta variants of SARS-CoV-2, jab maker Bharat Biotech informed on Wednesday.
The Covaxin booster dose trial was performed on subjects 6 months after they received the second dose of the vaccine.
Bharat Biotech in a Twitter post said that no paracetamol or painkillers are recommended after being vaccinated with Covaxin.
Bharat Biotech aims to conduct clinical trials on 5,000 subjects (50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin).
According to reports, Bharat Biotech has proposed that its nasal vaccine can be used as booster dose for those who have already been inoculated with Covaxin or Covishield vaccines against coronavirus.
Earlier last week, vaccine major Serum Institute of India had said that it has resumed exports of its vaccine Covishield to the international vaccine sharing program COVAX.
2 doses of COVID vaccine Covaxin (BBV152) are 50 pc effective against symptomatic COVID disease, according to 1st real-world assessment of COVID vaccine published in the Lancet Infectious Diseases journal.
The step will benefit more fully vaccinated Indians planning travel to the UK without the need for a pre-departure PCR test or self-isolation at the address declared on their compulsory Passenger Locator Forms.
Bharat Biotech was successful in releasing Covaxin in a record time and helped to save lives of crores of fellow Indians, says Director V Krishna Mohan.
The approval comes days after Covaxin received the emergency use listing from WHO.
Top News
Latest News
